CN1187053C - 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途 - Google Patents

糖皮质素受体拮抗剂用于制造治疗精神病药物的用途 Download PDF

Info

Publication number
CN1187053C
CN1187053C CNB988097923A CN98809792A CN1187053C CN 1187053 C CN1187053 C CN 1187053C CN B988097923 A CNB988097923 A CN B988097923A CN 98809792 A CN98809792 A CN 98809792A CN 1187053 C CN1187053 C CN 1187053C
Authority
CN
China
Prior art keywords
psychosis
psychotic
treatment
cortisol
glucocorticoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988097923A
Other languages
English (en)
Chinese (zh)
Other versions
CN1272788A (zh
Inventor
A·F·沙茨伯格
J·K·贝拉诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN1272788A publication Critical patent/CN1272788A/zh
Application granted granted Critical
Publication of CN1187053C publication Critical patent/CN1187053C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB988097923A 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途 Expired - Fee Related CN1187053C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
US60/060,973 1997-10-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200410039908XA Division CN1528315A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Publications (2)

Publication Number Publication Date
CN1272788A CN1272788A (zh) 2000-11-08
CN1187053C true CN1187053C (zh) 2005-02-02

Family

ID=22032889

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB988097923A Expired - Fee Related CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
CNA2006101003657A Pending CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法
CNA200410039908XA Pending CN1528315A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2006101003657A Pending CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法
CNA200410039908XA Pending CN1528315A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Country Status (17)

Country Link
US (2) US6150349A (enExample)
EP (1) EP1023074B1 (enExample)
JP (3) JP2001518509A (enExample)
KR (2) KR100840957B1 (enExample)
CN (3) CN1187053C (enExample)
AT (1) ATE332696T1 (enExample)
AU (1) AU747956B2 (enExample)
CA (1) CA2302586C (enExample)
CY (1) CY1106330T1 (enExample)
DE (1) DE69835225T2 (enExample)
DK (1) DK1023074T3 (enExample)
ES (1) ES2268792T3 (enExample)
IL (2) IL135469A0 (enExample)
NO (1) NO327233B1 (enExample)
NZ (1) NZ503250A (enExample)
PT (1) PT1023074E (enExample)
WO (1) WO1999017779A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EP1325022B1 (en) * 2000-09-18 2006-11-02 Applied Research Systems ARS Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
AU2002255845B2 (en) * 2001-03-23 2006-11-23 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
CN1527713A (zh) * 2001-05-04 2004-09-08 �Ƹ��� 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法
MXPA04000692A (es) * 2001-07-23 2004-04-21 Corcept Therapeutics Inc MeTODOS PARA EVITAR GANANCIA DE PESO INDUCIDA ANTISICOTICA.
DE60229411D1 (de) 2001-08-31 2008-11-27 Corcept Therapeutics Inc Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
EP1652526B1 (en) * 2001-10-26 2009-01-14 N.V. Organon Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
US8193172B2 (en) * 2001-11-23 2012-06-05 Pop Test Cortisol Llc Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
WO2004004653A2 (en) * 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferon-alpha therapy
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
AU2004208842B2 (en) * 2003-02-04 2009-05-28 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
WO2006060736A2 (en) * 2004-12-03 2006-06-08 The Children's Hospital Of Philadelphia A composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
CN100588393C (zh) * 2004-12-15 2010-02-10 上海三合生物技术有限公司 赛米司酮类用于治疗抑郁症的用途
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
EP2155204B1 (en) * 2007-06-15 2016-08-17 Research Triangle Institute Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
EP2576582B1 (en) * 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CA2984623C (en) 2015-05-18 2023-05-02 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for cushing's syndrome
CN114680890A (zh) * 2016-10-21 2022-07-01 西铁城时计株式会社 检测装置
EP3941460B1 (en) 2019-03-18 2025-10-15 Nieman, Lynnette K. Mifepristone for use in improving insulin sensitivity
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
EP0954317B1 (en) * 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Also Published As

Publication number Publication date
CY1106330T1 (el) 2011-10-12
KR20010024431A (ko) 2001-03-26
KR100840957B1 (ko) 2008-06-24
NZ503250A (en) 2001-09-28
IL135469A (en) 2007-03-08
AU747956B2 (en) 2002-05-30
DE69835225D1 (de) 2006-08-24
CN1272788A (zh) 2000-11-08
ATE332696T1 (de) 2006-08-15
WO1999017779A1 (en) 1999-04-15
EP1023074A1 (en) 2000-08-02
DE69835225T2 (de) 2007-07-05
NO20001744L (no) 2000-04-05
KR100804558B1 (ko) 2008-02-20
IL135469A0 (en) 2001-05-20
JP5180125B2 (ja) 2013-04-10
CN1919199A (zh) 2007-02-28
US6150349A (en) 2000-11-21
NO20001744D0 (no) 2000-04-05
NO327233B1 (no) 2009-05-18
CA2302586C (en) 2008-06-10
DK1023074T3 (da) 2006-11-06
JP2001518509A (ja) 2001-10-16
JP2009051858A (ja) 2009-03-12
KR20070032822A (ko) 2007-03-22
CN1528315A (zh) 2004-09-15
JP2009132743A (ja) 2009-06-18
US6362173B1 (en) 2002-03-26
PT1023074E (pt) 2006-12-29
EP1023074B1 (en) 2006-07-12
AU9683298A (en) 1999-04-27
CA2302586A1 (en) 1999-04-15
ES2268792T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
CN1187053C (zh) 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
CN1130200C (zh) 用于治疗痴呆的糖皮质激素受体拮抗剂
KR100895662B1 (ko) 글루코코르티코이드 수용체 특이적 길항제를 이용한스트레스 장애의 치료 방법
JP2005535664A (ja) インターフェロン−α治療に関連した精神病を処置するための方法
JP2003527342A (ja) 軽度認知障害を処置する方法
CN1556708A (zh) 抑制成年唐氏综合症患者认知退化的方法
US7884091B2 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
JP2009102346A (ja) グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
HK1104214A (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
AU2002303652A1 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
AU2006233254B8 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
EP1726307A2 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
ZA200308910B (en) Method for treating delerium using glucocorticoid receptor-specific antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050202

Termination date: 20151005

EXPY Termination of patent right or utility model